Novo Nordisk recalls batches of diabetes drugs

Batches of Novo Nordisk's diabetes treatments NovoMix 30 FlexPen and Penfill are being recalled, the European Medicines Agency said on Friday.

"In the affected cartridges the level of insulin may vary between 50 percent and 150 percent of the labelled insulin units, which could lead to or hyperglycaemia," the agency said in a statement.

Only a small percentage of cartridges, 0.14 percent, contain the wrong amount, the Danish company said.

Patients whose products were labelled with numbers from the affected batches should "make an appointment with their doctor or nurse for switching treatment as soon as it is feasible," the EU regulator said.

A spokesperson for the company was not immediately available on Friday afternoon.

Novo Nordisk has almost half the global insulin market, which has grown rapidly in recent years following a rise in the number of people suffering from diabetes, estimated by the World Health Organisation to stand at around 347 million.

add to favorites email to friend print save as pdf

Related Stories

Danish Novo Nordisk profit surges

Jan 31, 2013

Danish pharmaceutical company Novo Nordisk A/S on Thursday reported a 23 percent growth in fourth-quarter net profit on strong sales of diabetic drugs and gave a positive outlook as regulators worldwide begin to approve its ...

Novo Nordisk US shares skid on drug review setback (Update)

Feb 11, 2013

Shares of Novo Nordisk tumbled Monday after the Danish drugmaker said U.S. regulators need a new study before they can finish their review of two diabetes treatments, a development that could delay approval for several years.

Recommended for you

Progress in diabetes drug delivery

Jan 22, 2015

A drug therapy for diabetes treatment is being developed by an international research team led by WA scientists, which combines an existing anti-diabetic drug with bile acids to improve the drug's delivery ...

Roux-en-Y surgery can reverse insulin treatment in T2DM

Jan 21, 2015

(HealthDay)—Roux-en-Y gastric bypass surgery (RYGB) strongly predicts insulin cessation after surgery in insulin-treated type 2 diabetes (I-T2D) patients, independent of weight loss, according to a study ...

Unexpected turn in diabetes research

Jan 20, 2015

Years of diabetes research carried out on mice whose DNA had been altered with a human growth hormone gene is now ripe for reinterpretation after a new study by researchers at KU Leuven confirms that the gene had an unintended ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.